Aequus Pharmaceuticals Inc (AQS) — Cash Flow-to-Debt Ratio
Aequus Pharmaceuticals Inc (AQS) has a Cash Flow-to-Debt Ratio of 0.00x as of September 2025, meaning its operating cash flow of CA$-21.22K could theoretically repay 0% of its total liabilities (CA$7.09 Million) in one year. See how financially flexible is Aequus Pharmaceuticals Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Aequus Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Aequus Pharmaceuticals Inc across 12 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Aequus Pharmaceuticals Inc.
Annual Cash Flow-to-Debt Ratio for Aequus Pharmaceuticals Inc (2013–2024)
Year-by-year debt coverage analysis for Aequus Pharmaceuticals Inc. Check AQS cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CAD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.23x | CA$-1.66 Million | CA$7.26 Million | ▲ +46.5% |
| 2023 | -0.43x | CA$-2.29 Million | CA$5.38 Million | ▲ +32.9% |
| 2022 | -0.64x | CA$-1.95 Million | CA$3.07 Million | ▼ -38.8% |
| 2021 | -0.46x | CA$-1.17 Million | CA$2.56 Million | ▼ -45.7% |
| 2020 | -0.31x | CA$-804.91K | CA$2.56 Million | ▲ +50.8% |
| 2019 | -0.64x | CA$-1.63 Million | CA$2.55 Million | ▲ +92.2% |
| 2018 | -8.17x | CA$-2.57 Million | CA$314.90K | ▲ +21.3% |
| 2017 | -10.39x | CA$-3.81 Million | CA$366.84K | ▼ -73.2% |
| 2016 | -6.00x | CA$-4.47 Million | CA$744.41K | ▼ -78.9% |
| 2015 | -3.35x | CA$-3.84 Million | CA$1.15 Million | ▼ -82.9% |
| 2014 | -1.83x | CA$-1.36 Million | CA$744.51K | ▲ +88.1% |
| 2013 | -15.44x | CA$-876.06K | CA$56.74K | — |